Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,

Related Keywords

Germany ,Cambridge ,Cambridgeshire ,United Kingdom ,London ,City Of ,Japan ,Seoul ,Soult Ukpyolsi ,South Korea ,New York ,United States ,Tokyo ,Ingelheim ,Rheinland Pfalz ,Sosei Heptares ,Erica Hollingsworth ,Kentaro Tahara ,Frazer Hall ,Sosei Heptare ,Linda Ruckel ,Reinhard Malin ,Shinichiro Nishishita ,Maya Bennison ,Matt Barnes ,Hugh Marston ,Group Of Schizophrenias ,Schizophrenia Research ,Discovery Research At Boehringer Ingelheim ,Sosei Group ,Medistrava Consulting For International Media ,Youtube ,Sosei Group Corporation Heptares ,Sosei Group Corporation ,Boehringer Ingelheim ,Animal Health ,International Universities ,Tokyo Stock Exchange ,Linkedin ,Global Head ,Heptares Therapeutics ,Human Pharma ,Innovation Unit Comms ,Corporate Strategy ,International Media ,Heptares Forward Looking ,Anatomical Transcriptome ,Novel Therapeutic Candidate ,Psychiatric Disorders ,First Potent ,Orally Available Agonist ,Orphang Protein Coupled Receptor ,Make Coordinated Specialty Care Available ,Anyone Experiencing Early Schizophrenia ,Getting Over ,International Universities Press ,Suppresses Psychostimulant Behavior ,Structure Activity Relationships ,Suppress Psychostimulant Behavior ,Jacta Psychiatrica Scandinavica ,